SKP2 E3 Ligase Inhibitor III

Cell permeable: yes

Primary Target
Skp2

Reversible: yes

Toxicity: Standard Handling (A)

A cell-permeable benzothiazolylchromenone compound that disrupts Skp2-Skp1 interaction via direct Skp2 affinity binding and selectively prevents Skp2-, but not Fbw7- or β-TrCP-, Skp1-Cullin-1-F-box (SFC) complex-mediated substrates ubiquitination both in cell-free systems and in cultures, effectively preventing ubiquitination-dependent activation (Akt) and degradation (p21 & p27) of Skp2 substrates with concomitant down-regulation of cellular Skp2 protein level (10 to 20 µM in HEK293T & PC3 cultures). Exhibits antiproliferation activity toward a panel of 8 cancer (IC₅₀ from 1.22 to 10.5 µM), but not normal PNT1A epithelial or IMR90 fibroblast, lines and effectively reduces ALDH⁺ cancer stem cell (CSC; Cancer Initiating Cell) population in prostate cancer PC3 cultures (10 to 20 µM) by promoting p53-independent senescence and blocking Akt-dependent aerobic glycolysis. Exhibits good pharmacokinetic property (t_max = 1 h; t_1/2 >6 h; C_max >1 µM/plasma and >4 µM/tumor in 200 mm³ PC3 tumor-bearing mice; 80 mg/kg i.p.) and is efficacious in suppressing A549 and PC3 tumor growth in mice (40 to 80 mg/kg/d i.p.) in vivo.

Chan, C.H., et al. 2013 Cell154, 556.

Packaged under inert gas

Use only fresh DMSO for reconstitution.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany